CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.

摘要: The identification of human cancer antigens, the development techniques for active immunization against these and use adoptive transfer highly active, antigen-specific T cells have brightened prospects effective immunotherapies treatment patients with (1,2). Major efforts focused on increasing effectiveness antitumor responses sought to produce increasingly targeted cells. Recent murine models emphasized potential suppressor lymphocytes abrogate anticancer immune (3–5). The expression CD4+ CD25, α-chain trimeric interleukin (IL)-2 receptor, has been identified as a marker in (6–9). These shown protect from variety autoimmune diseases vivo, including oophoritis (6,7), gastritis (10), diabetes mellitus (6,11), thyroiditis (6). Moreover, vitro studies characterized hyporesponsive polyclonal cell receptor (TCR) stimulation suppressive when cocultured CD8+ (12,13). Recently, several papers isolated CD4+CD25+ peripheral blood mononuclear (PBMC) healthy humans (14–21). In response anti-CD3 mediated or alloantigen-mediated stimulation, purified exhibited phenotype functions similar volunteers led speculation that may play role abrogating cancer. We previously reactivity can be induced PBMC melanoma by immunizing peptide epitopes adjuvant, though it is not known if immunized also contain well (22). thus initiated resolve this question. If are demonstrated possess significant capabilities, future immunotherapy protocols need incorporate methods aimed at minimizing impediments responses.